SCA
ACRS icon

Secor Capital Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Secor Capital Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,860
Closed -$95K – 392
2018
Q4 		$95K Buy
+12,860
New +$133K 0.01% 454
2018
Q1 		– Sell
-58,507
Closed -$1.44M – 497
2017
Q4 		$1.44M Buy
+58,507
New +$1.42M 0.06% 241
2017
Q3 		– Sell
-18,370
Closed -$498K – 425
2017
Q2 		$498K Buy
+18,370
New +$499K 0.05% 347

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Secor Capital Advisors's ACRS Position: Q1 2019 in Review

Secor Capital Advisors sold out of Aclaris Therapeutics (ACRS) in Q1 2019, closing a stake of 12,860 shares — an estimated $95K sold.

Secor Capital Advisors first reported a position in ACRS in Q2 2017 and held it in 3 quarters. The position peaked at $1.44M in Q4 2017. 95 funds tracked by Wall St. Rank hold ACRS as of Q1 2019.

  • Secor Capital Advisors reported no remaining Aclaris Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 12,860 Aclaris Therapeutics shares in Q1 2019, an estimated $95K.
  • Secor Capital Advisors first reported a position in Aclaris Therapeutics in Q2 2017 and held it in 3 quarters.
  • Secor Capital Advisors's Aclaris Therapeutics position peaked at $1.44M in Q4 2017.
  • 95 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2019.

Based on Secor Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.